当前位置:首页 - 行情中心 - 双鹭药业(002038) - 财务分析 - 利润表

双鹭药业

(002038)

  

流通市值:74.93亿  总市值:90.41亿
流通股本:8.51亿   总股本:10.27亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入776,629,583.53583,506,665.49296,576,777.051,050,165,426.33
营业收入776,629,583.53583,506,665.49296,576,777.051,050,165,426.33
二、营业总成本552,257,886.29355,340,102.68176,977,771.71859,650,715.43
营业成本151,284,359.4397,104,759.5441,200,442.97156,955,919.82
税金及附加7,000,979.576,099,625.132,331,980.039,199,636.04
销售费用207,308,972.65141,159,095.5873,903,795.27426,799,168.27
管理费用97,111,862.8758,273,820.0227,670,771.8119,957,240.24
研发费用101,199,404.4261,098,329.7135,010,254.64161,649,390.87
财务费用-11,647,692.65-8,395,527.3-3,139,473-14,910,639.81
其中:利息费用---102,563.12
其中:利息收入11,021,524.127,409,322.63,156,811.6215,203,032.24
加:公允价值变动收益84,187,238.61108,112,364.36102,448,840.9921,301,941.32
加:投资收益54,498,062.9737,428,437.9320,472,754.5778,638,861.61
资产处置收益-710.91-710.91-205,403.58
资产减值损失(新)----1,810,572.11
信用减值损失(新)-25,560,930.68-28,040,933.41-16,161,393.69-31,943,285.46
其他收益7,116,902.644,692,325.014,489,785.716,410,121.75
营业利润平衡项目0000
四、营业利润344,612,259.87350,358,045.79230,848,992.92263,317,181.59
加:营业外收入28,238.9117,202.570.9230,143.71
减:营业外支出3,349.421,100.551,100.553,995,527.85
利润总额平衡项目0000
五、利润总额344,637,149.36350,374,147.81230,847,893.29259,351,797.45
减:所得税费用28,409,478.6534,194,814.9729,167,590.3331,009,768.84
六、净利润316,227,670.71316,179,332.84201,680,302.96228,342,028.61
持续经营净利润316,227,670.71316,179,332.84201,680,302.96228,342,028.61
归属于母公司股东的净利润317,568,080.9317,164,126.27201,929,706.82234,404,162.05
少数股东损益-1,340,410.19-984,793.43-249,403.86-6,062,133.44
(一)基本每股收益0.310.310.20.23
(二)稀释每股收益0.310.310.20.23
八、其他综合收益---13,326,806.52
归属于母公司股东的其他综合收益---13,652,867.35
九、综合收益总额316,227,670.71316,179,332.84201,680,302.96241,668,835.13
归属于母公司股东的综合收益总额317,568,080.9317,164,126.27201,929,706.82248,057,029.4
归属于少数股东的综合收益总额-1,340,410.19-984,793.43-249,403.86-6,388,194.27
公告日期2023-10-262023-08-252023-04-262023-04-26
审计意见(境内)标准无保留意见
TOP↑